Mainz Biomed BV Cash Flow Conversion Efficiency
Mainz Biomed BV cash flow conversion efficiency. Based on the latest financial reports, Mainz Biomed BV (MYNZ) has a cash flow conversion efficiency ratio of -6.957x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.46 Million) by net assets ($641.60K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mainz Biomed BV (2019–2025)
Cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2025. This chart illustrates how Mainz Biomed BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MYNZ live share price for real-time trading data and today's change.
Mainz Biomed BV Cash Flow Conversion Ratio Explained
Mainz Biomed BV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mainz Biomed BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mainz Biomed BV ranked by their cash flow conversion efficiency. Also see market cap of Mainz Biomed BV for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tian An Australia Ltd
AU:TIA
|
0.083x |
|
GT Biopharma Inc
NASDAQ:GTBP
|
-1.194x |
|
Platinex Inc
F:9PX
|
-0.108x |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
-0.039x |
|
Intanwijaya Internasional Tbk
JK:INCI
|
0.079x |
|
Cuscapi Berhad
KLSE:0051
|
0.081x |
|
MILA RESOUR. PLC LS-01
F:HN0
|
N/A |
|
Pan Entertainment Co. Ltd
KQ:068050
|
0.057x |
Annual Cash Flow Conversion Efficiency for Mainz Biomed BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mainz Biomed BV from 2019 to 2025. Review MYNZ free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $641.60K | $-10.98 Million | -17.113x | -505.46% |
| 2024-12-31 | $6.05 Million | $-17.09 Million | -2.826x | +58.14% |
| 2023-12-31 | $3.25 Million | $-21.94 Million | -6.752x | -544.41% |
| 2022-12-31 | $14.10 Million | $-14.77 Million | -1.048x | -106.97% |
| 2021-12-31 | $6.36 Million | $-3.22 Million | -0.506x | -396.10% |
| 2020-12-31 | $-2.74 Million | $-468.74K | 0.171x | -19.94% |
| 2019-12-31 | $-1.95 Million | $-416.50K | 0.214x | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more